Voyager Therapeutics (NASDAQ:VYGR) Share Price Passes Below Fifty Day Moving Average of $7.70

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $7.70 and traded as low as $6.11. Voyager Therapeutics shares last traded at $6.20, with a volume of 326,432 shares.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on VYGR. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Oppenheimer restated an “outperform” rating and set a $18.00 price target on shares of Voyager Therapeutics in a research report on Wednesday, May 15th. Wedbush reduced their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.83.

Voyager Therapeutics Price Performance

The firm’s 50 day moving average price is $7.70 and its 200 day moving average price is $8.28. The stock has a market capitalization of $337.24 million, a P/E ratio of -124.00 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The company had revenue of $29.58 million for the quarter, compared to the consensus estimate of $11.52 million. During the same quarter in the previous year, the business earned ($0.51) EPS. On average, equities research analysts forecast that Voyager Therapeutics, Inc. will post -1.44 earnings per share for the current year.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Great Point Partners LLC purchased a new position in Voyager Therapeutics during the 2nd quarter valued at $12,668,000. Farallon Capital Management LLC boosted its stake in shares of Voyager Therapeutics by 77.4% during the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after buying an additional 702,030 shares during the period. Armistice Capital LLC raised its stake in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in Voyager Therapeutics by 32.4% in the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after buying an additional 249,659 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.